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Abstract. Taxanes, paclitaxel and docetaxel (DTX) are 
anticancer agents that exhibit cytotoxicity by inhibiting micro-
tubule polymerization. They enhance the radiosensitivity of 
various cancers by blocking the cell cycle in the most radio-
sensitive G2/M phase. Recently, taxanes have been reported to 
have different mechanisms of action depending on dose inten-
sity. However, the mechanism of the radio-enhancing effect 
of DTX in relation to the drug dose intensity is not clearly 
understood. In the present study, we experimentally investi-
gated the radio-enhancing effects of various concentrations 
of DTX against esophageal squamous cell cancer (ESCC); 
KES cells were used for in vitro confirmation of the effec-
tive administration schedule for DTX in chemoradiotherapy 
involving ESCC. DTX enhanced radiation cell killing in a 
concentration-dependent manner in KES cells. High cytotoxic 
concentrations (>10 nM) of DTX strongly enhanced radiosen-
sitivity. Low concentrations (<1 nM) of DTX that did not have 
a cytotoxic effect showed a radio-enhancing effect by inducing 
DNA double strand breaks and apoptosis after irradiation. 
Low and high concentrations of DTX induced radiosensitive 
G0/G1 and G2/M phase arrest, respectively in KES cells. Cells 
treated with high concentrations of DTX exhibited nuclear 
aggregation associated with apoptotic change. In contrast, 
cells treated with low concentrations of DTX displayed multi-
nucleation or unequal division. In conclusion, enhancement of 
the radiosensitivity of ESCC cells by DTX was demonstrated, 
even using nanomolar concentrations that did not have a cyto-
toxic effect. DTX has different radio-enhancing mechanisms 
depending on its concentration. Therefore, weekly administra-
tion of DTX might effectively enhance radiation cytotoxicity 
in the treatment of ESCC.
Introduction
The treatment outcome for patients with esophageal squamous 
cell carcinoma (ESCC) is poor, despite improvements in care 
(1). There have been several treatment strategies for ESCC; 
among them, surgery is considered as the most effective. 
However, patients with unresectable or inoperable disease are 
usually treated with chemoradiotherapy (CRT) in the clinic; 
this is considered to be an effective therapeutic strategy (2-4). 
At present, the standard regimen for CRT regarding ESCC is the 
combined use of cisplatin and 5-fluorouracil with radiotherapy. 
CRT sometimes induces severe adverse events, together with 
a favorable therapeutic effect (5,6). Therefore, a CRT regimen 
involving reduced side effects is desirable. Taxanes including 
docetaxel (DTX) and paclitaxel (PTX) are anticancer agents 
that exhibit cytotoxicity by inhibiting microtubule polymer-
ization; they are attracting attention as one of the key drugs 
in the treatment of a variety of carcinomas (7). Among them, 
DTX is useful for many types of cancer including nasopha-
ryngeal (8), gastric (9,10), breast (11), prostate (12), lung (13), 
thyroid (14) and esophageal cancer (15). It has been widely 
recognized that DTX enhances radiosensitivity in various 
cancers in vitro and in vivo (16-18). To date, DTX has been 
shown to be clinically useful as an active agent in CRT treat-
ment regimens involving laryngeal/hypopharyngeal cancers 
(19). DTX has been used in combination with cisplatin as an 
agent for CRT in non-small cell lung cancer (20). A phase I/II 
study involving DTX and cisplatin with concurrent thoracic 
radiotherapy for locally advanced non-small cell lung cancer 
has shown that the dose limiting toxicity is radiation esopha-
gitis (21). One of the approaches regarding the reduction of 
adverse events in CRT is the administration of low dose DTX. 
Concentration-dependent radiosensitizing effect of docetaxel  
in esophageal squamous cell carcinoma cells
SHOHEI MIYANAGA1,  ITASU NINOMIYA1,  TOMOYA TSUKADA1,  KOICHI OKAMOTO1,  SHINICHI HARADA2,   
SHINICHI NAKANUMA1,  SEISHO SAKAI1,  ISAMU MAKINO1,  JUN KINOSHITA1,  HIRONORI HAYASHI1,  
KEISHI NAKAMURA1,  KATSUNOBU OYAMA1,  HISATOSHI NAKAGAWARA1,  TOMOHARU MIYASHITA1,  
HIDEHIRO TAJIMA1,  HIROYUKI TAKAMURA1,  SACHIO FUSHIDA1  and  TETSUO OHTA1
1Department of Gastroenterological Surgery, Division of Cancer Medicine, Graduate School of Medical Science,  
2Center for Biomedical Research and Education, School of Medical Science, Kanazawa University, Kanazawa 920-8641, Japan
Received October 12, 2015;  Accepted November 13, 2015
DOI: 10.3892/ijo.2015.3291
Correspondence to: Dr Itasu Ninomiya, Department of Gastroentero-
logical Surgery, Division of Cancer Medicine, Graduate School of 
Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa 
920-8641, Japan
E-mail: nino@staff.kanazawa-u.ac.jp
Abbreviations: CRT, chemoradiotherapy; DTX, docetaxel; ESCC, 
esophageal squamous cell carcinoma; MTT, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered 
saline; PTX, paclitaxel; γH2AX, H2AX phosphorylation
Key words: esophageal cancer, docetaxel, radiation, radiosensitizing 
effect, cell cycle, double-strand DNA breaks
MIYANAGA et al:  RADIOSENSITIzING EFFECT OF DOCETAXEL IN ESOPHAGEAL CANCER518
Recently, there have been several reports concerning the favor-
able effects of weekly administration of low dose DTX as a 
radiosensitizer in head and neck cancer (22-26), non-small cell 
lung cancer (27,28) and ovarian cancer (29). These studies have 
shown that CRT with low dose DTX has an antitumor effect 
comparable to high dose DTX, and induce less adverse events. 
In recent years, CRT in combination with weekly DTX has 
been performed safely in patients with advanced inoperable 
ESCC (30,31). Preoperative CRT for locally advanced ESCC 
using DTX results in similar or better long-term outcomes as 
compared with cisplatin and 5-fluorouracil based CRT, despite 
the patients demonstrating a better pathological response to 
cisplatin and 5-fluorouracil based CRT when compared with 
DTX based CRT (32).
DTX induces microtubule modification and causes cells to 
accumulate in the radiosensitive G2/M phase of the cell cycle 
(33). Recently, taxanes have been reported to have a different 
mechanism of action depending on dose intensity (34-36). 
Most studies that have indicated a dual mechanism of action 
for taxanes have been reported using PTX (34,36). The mecha-
nism of the radio-enhancing effect of DTX in relation to the 
dose intensity is not clearly understood.
In the present study, we experimentally investigated the 
radio-enhancing effects of various concentrations of DTX 
against ESCC cells to elucidate an effective administration 
schedule for DTX regarding CRT for ESCC. We also exam-
ined the concentration-dependent radio-enhancing mechanism 
in respect to cell cycle arrest in ESCC cells.
Materials and methods
Cell line and treatment. The esophageal squamous cell carci-
noma cell line KES has been established in our laboratory from 
endoscopic biopsy specimens obtained from a patient carrying 
well differentiated esophageal squamous cell carcinoma. 
KES was cultured in RPMI-1640 (Invitrogen, Osaka, Japan) 
supplemented with 10% heat-inactivated fetal bovine serum 
(Nissui Pharmaceutical Co. Ltd., Tokyo, Japan), 100 IU/ml 
penicillin, 100 µg/ml streptomycin (Invitrogen), 2 mM gluta-
mine (Nissui Pharmaceutical Co. Ltd.) and 0.5 mM sodium 
pyruvate at 37˚C in a humidified atmosphere of CO2 in air. 
DTX was dissolved in phosphate-buffered saline (PBS) to a 
stock concentration of 200 nM and stored at -20˚C. Cultures 
were irradiated using MBR-1520R-3 X-ray radiation apparatus 
(Hitachi Medicotechnology, Hitachi, Japan) at a dose rate of 
1 Gy/min. Power output of the X-rays used for irradiation was 
125 kV and the beam current was 20 mA. Forward-scattered 
radiation, and 0.5 mm Al and 0.2 mm Cu filters were used.
Cell growth assay. The viability of cells treated with DTX 
was determined using a standard 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. KES cells were 
treated with DTX at various concentrations (0.1-50 nM) for 
48 h. The percentage inhibition was determined by comparing 
the cell density of the drug-treated cells with that of untreated 
controls. All experiments were repeated at least three times.
Cell cycle analysis. KES cells were treated with DTX at 
various concentrations (0.1-50 nM), following treatment 
periods of 0, 3, 6, 12, 24 and 48 h. Cells were stained with 
propidium iodide and analyzed using flow cytometry. The 
percentages of the cells in the sub-G0, G0/G1, S and G2/M 
phases were calculated.
Nuclear form. Alteration of the nuclear form of the KES cells 
treated with DTX was analyzed. KES cells were treated with 
DTX at various concentrations (0, 1 and 10 nM), and were 
fixed with 4% formaldehyde and stained with Hoechst 33342 
(Thermo Fisher Scientific K.K, Yokohama, Japan). Nuclear 
form was examined using an Olympus immunofluorescence 
microscope (BX50/BX-FLA, Olympus, Tokyo, Japan).
Clonogenic assay. The cells were plated into dishes and 
allowed to attach for 4 h. The medium was then replaced by 
a medium with or without DTX. Following incubation for 
12 h, the cells were irradiated at various doses (2-6 Gy). The 
cells were harvested using trypsinization, counted, and known 
concentrations of cells were re-plated into 100-mm culture 
dishes and returned to the incubator. After incubation for 
7-10 days, the cell colonies were fixed and stained with 0.1% 
crystal violet. Colonies of >50 cells were manually counted to 
determine survival.
Assessment of apoptosis. The Annexin V binding assay was 
used to assess phosphatidylserine externalization as a marker 
of apoptosis using the Pacific Blue™ Annexin V/SYTOX® 
AADvanced™ Apoptosis kit (Invitrogen) according to the 
manufacturer's instructions. The extent of apoptosis was quan-
tified using flow cytometry.
Immunofluorescent cytochemistry. Cells were cultured on 
Lab-Tec chamber slides (Nalge Nunc International, Rochester, 
NY, USA). The cells were then treated with various concen-
trations of DTX (0, 1 and 10 nM) for 12 h and subsequently 
irradiated. They were fixed in a mixture of methanol and 
acetone (1:1) for 15 min. The slides were immersed in methanol 
containing 0.3% H2O2 for 30 min, blocked with 3.3% normal goat 
serum in PBS and incubated with anti-phosphohistone H2AX 
(Ser 139) (Cell Signaling Technology, MA, USA) at 4˚C. After 
sections were washed in PBS, immunoreactivity was visualized 
by incubating them in anti-rabbit IgG antibody conjugated with 
Alexa Flour 488 (Molecular Probes, Eugene, OR, Danvers, MA, 
USA) for 1 h at room temperature. The nucleus was counter-
stained with Hoechst 33342 (Thermo Fisher Scientific K.K). 
The slides were examined with an Olympus immunofluores-
cence microscope (BX50/BX-FLA, Olympus).
Results
Antitumor efficacy of DTX. The inhibitory effect of DTX on 
KES cell growth was assessed using the MTT assay. Cells 
were treated with various concentrations of DTX for 48 h. 
DTX inhibited KES cell growth in a dose-dependent manner 
(Fig. 1). The 50% inhibitory concentration (IC50) value of DTX 
was 2.4 nM and the 20% inhibitory concentration (IC20) value 
was 1.1 nM.
Cell cycle. First, no obvious cell cycle change was observed 
below 6-h exposure to DTX at any concentration. After 12-h 
incubation of KES cells with the medium and high concentra-
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tions of DTX (5-50 nM and more), ~65% of the cells were 
arrested in the G2-M phase with a 4-n content of DNA (Figs. 2 
and 3 and Table I). The accumulation of cells in the sub-G0 
and G0/G1 phases was observed after treatment using low 
concentrations of DTX (0.5-1 nM). Low concentrations of 
DTX led to the development of hypodiploid cells.
Nuclear form. KES cells were stained with Hoechst 33342 after 
treatment with two concentrations of DTX (0.1 and 10 nM) for 
12 h. Nuclear form was investigated using an immunofluores-
cence microscope. Cells treated with a high concentration of 
DTX exhibited nuclear aggregation associated with apoptotic 
change in some nuclei. In contrast, cells treated with a low 
Figure 1. Antitumor efficacy of docetaxel (DTX). Antitumor efficacy of DTX was assessed using the MTT assay. KES cells were treated with DTX at various 
concentrations (0.1-50 nM) for 48 h.
Figure 2. Cell cycle alteration caused by docetaxel (DTX) in a concentration-dependent manner. KES cells were incubated for 12 h with various concentrations 
of DTX (0, 0.1, 0.5, 1.0, 5, 10 and 50 nM). Cell cycle alteration after treatment was analyzed using flow cytometry. Relative to the control (0 nM), cells treated 
with low concentrations of DTX (0.5-1.0 nM) were arrested in the G1 phase (black arrow). Cells treated with high concentrations of DTX (5-50 nM) were 
arrested at G2-M phase (white arrow).
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concentration of DTX exhibited multi-nucleation or unequal 
division in some nuclei (Fig. 4).
Radiosensitizing effect of DTX. The radio-sensitizing effect of 
DTX was assessed using a clonogenic assay. As expected, cells 
treated with 10 nM DTX (high concentration) had enhanced 
radio-sensitivity (Fig. 5). In addition, cells treated with 1 nM 
DTX (low concentration) exhibited enhanced radio-sensitivity 
although it was slightly lower than after treatment with the 
high concentration of DTX.
Enhancement of radiation-induced apoptosis using DTX. The 
apoptotic response to irradiation alone or the combination of 
Figure 3. Sequential cell cycle alteration caused by docetaxel (DTX). KES cells were incubated with low (1.0 nM) or high (10 nM) concentrations of DTX for 
0-48 h. Cell cycle alteration after treatment was analyzed by flow cytometry.
Table I. Cell cycle distribution of KES cells following docetaxel 
(DTX) treatment.
 Proportion of cell cycle
 fraction (%)
 ------------------------------------------------------------------------
DTX concentration Sub-G0/G1+ G0/G1 S G2/M
(nM)
  0 59.0 11.6 29.2
  1 71.9   9.6 18.3
10 21.1 11.8 66.8
Figure 4. Effects of docetaxel (DTX) on nuclear morphology. KES cells were treated with various concentrations of DTX (0 nM, 1 nM and 10 nM) for 12 h. 
Cells were fixed with 4% formaldehyde and stained with Hoechst 33342. Nuclear morphology was examined using an immunofluorescence microscope. 
(A) Control. (B) Cells treated with a low concentration DTX (1 nM). Some nuclei show multi-nucleation or unequal division (arrow a). (C) Cells treated with a 
high concentration of DTX (10 nM). Some nuclei exhibit nuclear aggregation associated with apoptotic change (arrow b). Scale bar, 10 µm.
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irradiation and DTX treatment was assessed. After treatment 
with various concentrations of DTX (0, 1 and 10 nM) for 12 h, 
KES cells were irradiated (4 Gy) and returned to culture for 
6 h. The cells were then examined for the detection of apop-
tosis. Even without DTX, apoptosis was induced in a few cells 
by irradiation. A high concentration of DTX (10 nM) remark-
ably enhanced radiation-induced apoptosis. In addition, a low 
concentration of DTX (1 nM) also enhanced radiation and 
induced a certain degree of apoptosis in KES cells (Fig. 6).
Enhancement of radiation induced DNA double strand breaks 
(DSBs) using DTX. After irradiation, H2AX phosphorylation 
(γH2AX) was measured as an indicator of DNA DSBs using 
immunofluorescent cytochemistry. In the absence of DTX, 
few cells showed γH2AX foci after irradiation. A high concen-
tration of DTX (10 nM) induced multiple γH2AX foci after 
Figure 5. Radiosensitizing effect of docetaxel (DTX) on KES cells. The 
survival fraction of KES cells after radiation treatment in combination with 
DTX (low concentration, 1 nM; high concentration, 10 nM) for 12 h, or after 
radiation treatment without DTX, was measured by clonogenic assay. Results 
represent the means of three independent experiments with standard errors.
Figure 6. The effect of docetaxel (DTX) on apoptosis after irradiation. KES cells were treated with DTX (low concentration, 1 nM; high concentration, 10 nM) 
for 12 h and irradiated (dose, 4 Gy). Phosphatidylserine externalization as a marker of apoptosis was assessed by means of the Annexin V binding assay using 
the Pacific Blue Annexin V/SYTOX AADvanced Apoptosis kit. The extent of apoptosis was quantified using flow cytometry. Early apoptotic populations were 
localized in the lower right quadrants.
Figure 7. The effect of docetaxel (DTX) on radiation-induced DNA double strand breaks (DSBs). KES cells were treated with DTX for 12 h and irradiated 
(dose, 4 Gy). DNA DSBs were assessed by observation of phosphorylated histone H2AX (γ-H2AX) foci stained with Alexa Flour 488 (γH2AX) (green) using 
an immunofluorescence microscope. The cell nucleus was stained with Hoechst 33342 (blue). (A) Control (0 nM). (B) Cells treated with a low concentration 
of DTX (1 nM). (C) Cells treated with a high concentrationof DTX (10 nM). Scale bar, 1 µm.
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irradiation in many cells. A low concentration of DTX (1 nM) 
induced a certain degree of γH2AX foci after irradiation in 
several KES cells (Fig. 7).
Discussion
In the present study, we found that DTX had a concentration-
dependent radio-enhancing effect in ESCC cells. A high 
cytotoxic concentration (>10 nM) of DTX strongly enhanced 
radiosensitivity. A low concentration (<1 nM) of DTX, that did 
not elicit a cytotoxic effect, also achieved a radio-enhancing 
effect by inducing DNA DSBs and apoptosis after irradiation. 
Low and high concentrations of DTX induced radiosensitive 
G0/G1 and G2/M phase arrest, respectively, in ESCC cells.
Taxanes have demonstrated activity as a radiosensitizer 
in a number of preclinical and clinical studies by inhibiting 
the depolymerization of microtubules, and blocking the cell 
cycle in the most radiosensitive phase of the cell cycle (G2/M). 
In various tumor cells, the G2/M phase is the most sensitive 
regarding radiation in comparison with normal cells because 
of deficient DNA repair during the G2-prophase period of 
the cell cycle (37,38). Conversely, cells are known to be most 
radio-resistant in the late S phase. We found that a high 
concentration of DTX (10 nM) induced the accumulation of 
cells in the G2/M phase and strongly enhanced the radiosensi-
tivity of ESCC cells. Recently, taxanes have been reported to 
have a different mechanism of action depending on DTX dose 
intensity (34-36). It is well known that a high concentration of 
DTX (100 nM) arrests cells in the G2/M phase. A low concen-
tration of DTX can induce aberrant mitosis (39,40). There 
has been limited evidence published concerning the effect of 
low concentrations of DTX concerning cell cycle arrest. The 
present study showed that a low concentration of DTX (1 nM) 
induced the accumulation of ESCC cells in the sub-G0 and 
G0/G1 phases, indicating G0/G1 arrest. Morphologically, a 
low concentration of DTX induces multi-nucleation or unequal 
division. The cells are known to be most radioresistant in the 
S phase and most radiosensitive in the G2/M phase. A low 
concentration of DTX may contribute to the enhancement of 
radiosensitivity in ESCC cells by means of cell cycle arrest 
in the radiosensitive G0/G1 phase and the induction of multi-
nucleation or unequal division.
In the present study, although a low concentration of DTX 
induced very little apoptosis, irradiated cells after pretreatment 
with a low concentration of DTX exhibited a higher popula-
tion of apoptotic cells relative to those irradiated without DTX 
pretreatment. In addition, after irradiation apoptotic cells are 
associated with an increased level of γH2AX. When DNA 
DSBs are induced by radiation, the histone H2AX is rapidly 
phosphorylated and forms γH2AX at the sites of the DSBs. 
Thus, γH2AX is considered as an indicator of DSBs. In the 
present study, we found that a low concentration of DTX, that 
did not cause a cytotoxic effect, could enhance radiosensitivity 
by enhancing radiation-induced DSBs and apoptosis.
Pradier et al (41) speculated that DTX seemed to be a 
better radiosensitizer for squamous cell carcinoma cells than 
PTX, because DTX enhances the radiosensitivity at lower 
concentrations than PTX. Cancer cells tested in vitro had IC50 
values for DTX ranging from 5 to 50 nM (42). However, the 
radiosensitizing activity of DTX in vitro was achieved even at 
subnanomolar concentrations. DTX concentrations as low as 
0.07 nM have been shown to potentiate the effects of irradia-
tion in cell lines (41). Plasma levels of DTX reach their peak 
just after injection, and are metabolized relatively quickly. 
The pharmacokinetics and metabolism of DTX in vivo has 
been shown to have a three phase disposition profile with a 
terminal half-life of 12 h (43). DTX may be present for as 
long as 1 week, thus supporting the use of weekly DTX (44). 
From the elimination curve for patients receiving 20 mg/m2 
of DTX, it can be speculated that the plasma concentration of 
DTX is maintained at a relatively high level (>5 nM) for ~48 h 
after administration, and at a relatively low level (~1 nM) after 
48 h (44). It is speculated that DTX at a high plasma concentra-
tion has a cytotoxic effect and a strong radio-enhancing effect 
as a result of cell cycle arrest in the G2/M phase within 48 h 
after administration; however, thereafter the cytotoxic effect 
may disappear because of drug metabolization, maintaining 
its radio-enhancing activity as a result of cell cycle arrest in 
the G0/G1 phase. These results support the clinical use of 
weekly low dose DTX in combination with radiotherapy as 
reported in patients with oropharyngeal and hypopharyngeal 
carcinoma, non-small cell lung cancer and ESCC (26,28,31).
Hennequin et al (16) reported that the radio-enhancing 
effect of taxoids varies from one cell line to another. DTX and 
PTX can reduce or enhance radiation cell killing, depending 
on the drug concentration. The full dosage of taxoids may 
provide suitable conditions for supra-additive interaction with 
radiation during concomitant exposure; conversely, induced 
radiation resistance by taxoids may occur in the low-drug 
dose range. An in vivo study indicated that the high level 
of radiation enhancement achieved by PTX occurs not at 
the time of the highest mitotic arrest but at 1 day after PTX 
treatment (45); this indicates that PTX potentiates tumor 
radio-responsiveness by mechanisms in addition to the 
blocking of the cell cycle in mitosis, by tumor reoxygenation of 
hypoxic tumor cells (46). In addition, wild-type p53 function 
is required to confer tumor cell sensitivity to DNA-damaging 
agents, such as ionizing radiation; the loss of p53 function in 
certain human tumor cells can lead to resistance to ionizing 
radiation (47). In the present study, we examined the radio-
enhancing effect of DTX in ESCC using the KES cell line 
that was newly established in our department, because KES 
cells are transplantable into the nude mouse. The p53 status 
in KES cells has not yet been investigated. To confirm the 
radiosensitizing effect of DTX according to its concentration 
in ESCC cells, further study to investigate its effects in other 
ESCC cell lines showing different p53 function in vitro is 
required. Furthermore, the radio-enhancing effect of DTX 
should be confirmed in vivo using a KES cell xenograft nude 
mouse model.
In conclusion, enhancement of the radiosensitivity of ESCC 
cells using DTX was demonstrated in vitro in the present study, 
even at a nanomolar concentration that did not induce cyto-
toxic effects. DTX has different radio-enhancing mechanisms 
that are concentration-dependent. Weekly administration of 
DTX might effectively enhance radiation cytotoxicity against 
ESCC. It will be necessary to elucidate the radio-enhancing 
mechanism of DTX in vivo. In addition, the benefit of weekly 
administration of low dose DTX in CRT regimens will need to 
be verified in the clinic.
INTERNATIONAL JOURNAL OF ONCOLOGY  48:  517-524,  2016 523
References
  1. Castro C, Bosetti C, Malvezzi M, Bertuccio P, Levi F, Negri E, 
La Vecchia C and Lunet N: Patterns and trends in esophageal 
cancer mortality and incidence in Europe (1980-2011) and 
predictions to 2015. Ann Oncol 25: 283-290, 2014.
  2. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, 
Satake M, Ishikura S, Ogino T, Miyata Y, et al: Definitive 
chemoradiotherapy for T4 and/or M1 lymph node squamous 
cell carcinoma of the esophagus. J Clin Oncol 17: 2915-2921, 
1999.
  3. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, 
Schuller DE and Forastiere AA: An intergroup phase III 
comparison of standard radiation therapy and two schedules 
of concurrent chemoradiotherapy in patients with unresectable 
squamous cell head and neck cancer. J Clin Oncol 21: 92-98, 
2003.
  4. Ishida K, Ando N, Yamamoto S, Ide H and Shinoda M: Phase II 
study of cisplatin and 5-fluorouracil with concurrent radiotherapy 
in advanced squamous cell carcinoma of the esophagus: A Japan 
Esophageal Oncology Group (JEOG)/Japan Clinical Oncology 
Group trial (JCOG9516). Jpn J Clin Oncol 34: 615-619, 2004.
  5. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, 
Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: 
Combined chemotherapy and radiotherapy compared with radio-
therapy alone in patients with cancer of the esophagus. N Engl J 
Med 326: 1593-1598, 1992.
  6. Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, 
Yamamoto T, Kitahara T, Mizutani Y, Ohtsu A, et al: Definitive 
chemoradiotherapy for patients with malignant stricture due 
to T3 or T4 squamous cell carcinoma of the oesophagus. Br J 
Cancer 88: 18-24, 2003.
  7. Choy H: Taxanes in combined modality therapy for solid tumors. 
Crit Rev Oncol Hematol 37: 237-247, 2001.
  8. Ngeow J, Lim WT, Leong SS, Ang MK, Toh CK, Gao F, 
Chowbay B and Tan EH: Docetaxel is effective in heavily 
pretreated patients with disseminated nasopharyngeal carcinoma. 
Ann Oncol 22: 718-722, 2011.
  9. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, zuber E, 
Daglish B, Boudraa Y, Kim WS, Heo DS, et al: Docetaxel 75 
mg/m(2) is active and well tolerated in patients with metastatic 
or recurrent gastric cancer: A phase II trial. Jpn J Clin Oncol 32: 
248-254, 2002.
10. Abbrederis K, Lorenzen S, von Weikersthal LF, Vehling-
Kaiser U, Schuster T, Rothling N, Peschel C and Lordick F: 
Weekly docetaxel monotherapy for advanced gastric or esopha-
gogastric junction cancer. Results of a phase II study in elderly 
patients or patients with impaired performance status. Crit Rev 
Oncol Hematol 66: 84-90, 2008.
11. Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, 
Labonia V, Rossi E, De Maio E, Piccirillo MC, et al: Effects 
on quality of life of weekly docetaxel-based chemotherapy 
in patients with locally advanced or metastatic breast cancer: 
Results of a single-centre randomized phase 3 trial. BMC Cancer 
11: 75, 2011.
12. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Serment G, 
Camerlo J, Genre D, Bardou VJ, Maraninchi D and Viens P: 
Weekly administration of docetaxel for symptomatic metastatic 
hormone-refractory prostate carcinoma. Cancer 98: 1627-1634, 
2003.
13. Perng RP, Shih JF, Chen YM, Chou KC, Lee YC and Tsai CM: 
A phase II study of single-agent docetaxel chemotherapy for 
non-small cell lung cancer. Jpn J Clin Oncol 30: 429-434, 
2000.
14. Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, 
Sawaki M, Kikumori T, Fujimoto Y, Arima H, Imai T, et al: The 
feasibility study of docetaxel in patients with anaplastic thyroid 
cancer. Jpn J Clin Oncol 40: 596-599, 2010.
15. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, 
Fujita H, Takiyama W and Ohtsu T: A phase II study of single-
agent docetaxel in patients with metastatic esophageal cancer. 
Ann Oncol 15: 955-959, 2004.
16. Hennequin C, Giocanti N and Favaudon V: Interaction of ionizing 
radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in 
HeLa and SQ20B cells. Cancer Res 56: 1842-1850, 1996.
17. Balcer-Kubiczek EK, Attarpour M, Wang Jz and Regine WF: 
The effect of docetaxel (taxotere) on human gastric cancer cells 
exhibiting low-dose radiation hypersensitivity. Clin Med Oncol 
2: 301-311, 2008.
18. Mason KA, Hunter NR, Milas M, Abbruzzese JL and Milas L: 
Docetaxel enhances tumor radioresponse in vivo. Clin Cancer 
Res 3: 2431-2438, 1997.
19. Yoshida T, Tokashiki R, Itoh H, Nakamura K, Hiramatsu H, 
Tsukahara K, Shimizu S, Takada D, Okamoto I, Abe K, et al: A 
phase I-II study of bi-weekly docetaxel combined with radiation 
therapy for patients with cancer of the larynx/hypopharynx. Jpn 
J Clin Oncol 37: 641-646, 2007.
20. Li YQ, Shi AH, Li FH, Yu R and zhu GY: Phase I study to 
determine MTD of docetaxel and cisplatin with concurrent 
radiation therapy for Stage III non-small cell lung cancer. Chin J 
Cancer Res 23: 129-133, 2011.
21. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, 
Hiraki S, Watanabe Y, Bessho A, Eguchi K, et al; Okayama Lung 
Cancer Study Group: Phase I/II study of docetaxel and cisplatin 
with concurrent thoracic radiation therapy for locally advanced 
non-small-cell lung cancer. Br J Cancer 89: 795-802, 2003.
22. Tishler RB, Norris CM Jr, Colevas AD, Lamb CC, Karp D, 
Busse PM, Nixon A, Frankenthaler R, Lake-Willcutt B, 
Costello R, et al: A Phase I/II trial of concurrent docetaxel and 
radiation after induction chemotherapy in patients with poor 
prognosis squamous cell carcinoma of the head and neck. Cancer 
95: 1472-1481, 2002.
23. Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, 
Okami K and Inuyama Y; Japan Cooperative Head and Neck 
Oncology Group (JCHNOG): Phase I/II trial of weekly docetaxel 
and concomitant radiotherapy for squamous cell carcinoma of 
the head and neck. Int J Clin Oncol 9: 107-112, 2004.
24. Tishler RB, Posner MR, Norris CM Jr, Mahadevan A, Sullivan C, 
Goguen L, Wirth LJ, Costello R, Case M, Stowell S, et al: 
Concurrent weekly docetaxel and concomitant boost radiation 
therapy in the treatment of locally advanced squamous cell 
cancer of the head and neck. Int J Radiat Oncol Biol Phys 65: 
1036-1044, 2006.
25. Clark JI, Eisner RM, Hofmeister C, Norton J, Thomas S, 
Choudhury A, Petruzzelli G, Lathers D, Young MR, Lau A, et al: 
Phase I adjuvant radiation with docetaxel in high-risk head and 
neck cancer. Am J Clin Oncol 32: 396-400, 2009.
26. Fukada J, Shigematsu N, Takeda A, Ohashi T, Tomita T, 
Shiotani A, Kunieda E, Kawaguchi O, Fujii M and Kubo A: 
Weekly low-dose docetaxel-based chemoradiotherapy for locally 
advanced oropharyngeal or hypopharyngeal carcinoma: A retro-
spective, single-institution study. Int J Radiat Oncol Biol Phys 76: 
417-424, 2010.
27. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, 
Araki T, Nishikawa K and Ishihara H: Concurrent two-dimen-
sional radiotherapy and weekly docetaxel in the treatment of 
stage III non-small cell lung cancer: A good local response but 
no good survival due to radiation pneumonitis. Lung Cancer 40: 
79-84, 2003.
28. Brunsvig PF, Hatlevoll R, Berg R, Lauvvang G, Owre K, Wang M 
and Aamdal S: Weekly docetaxel with concurrent radiotherapy 
in locally advanced non-small cell lung cancer: A phase I/II 
study with 5 years' follow-up. Lung Cancer 50: 97-105, 2005.
29. Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, 
Yamada SD, Waggoner SE, Mohiuddin M and Fracasso PM: 
Low-dose abdominal radiation as a docetaxel chemosensitizer 
for recurrent epithelial ovarian cancer: A phase I study of 
the Gynecologic Oncology Group. Gynecol Oncol 120: 224-228, 
2011.
30. Font A, Arellano A, Fernández-Llamazares J, Casas D, Boix J, 
Cardenal J, Margelí M, Manzano JL, Abad A and Rosell R: 
Weekly docetaxel with concomitant radiotherapy in patients with 
inoperable oesophageal cancer. Clin Transl Oncol 9: 177-182, 
2007.
31. Makino I, Okamoto K, Kinoshita J, Hayashi H, Nakamura K, 
Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura H, et al: 
A pilot study of chemoradiotherapy with weekly docetaxel for 
thoracic esophageal carcinoma with T4 and/or M1 lymph node 
metastasis. World J Oncol 2: 252-258, 2011.
32. Kushida T, Nohara S, Yoshino K, Fujiwara D, Ouchi K, Amano T, 
Isayama F, Tomita N, Iwanuma Y, Sasai K, et al: Utility of 
weekly docetaxel combined with preoperative radiotherapy for 
locally advanced esophageal cancer from pathological analysis. 
Dis Esophagus 27: 368-373, 2014.
33. Moos PJ and Fitzpatrick FA: Taxanes propagate apoptosis via 
two cell populations with distinctive cytological and molecular 
traits. Cell Growth Differ 9: 687-697, 1998.
34. Torres K and Horwitz SB: Mechanisms of Taxol-induced cell death 
are concentration dependent. Cancer Res 58: 3620-3626, 1998.
MIYANAGA et al:  RADIOSENSITIzING EFFECT OF DOCETAXEL IN ESOPHAGEAL CANCER524
35. Hernández-Vargas H, Palacios J and Moreno-Bueno G: Telling 
cells how to die: Docetaxel therapy in cancer cell lines. Cell 
Cycle 6: 780-783, 2007.
36. zhang D, Yang R, Wang S and Dong z: Paclitaxel: New uses for 
an old drug. Drug Des Devel Ther 8: 279-284, 2014.
37. Chaffey JT and Hellman S: Differing responses to radiation 
of murine bone marrow stem cells in relation to the cell cycle. 
Cancer Res 31: 1613-1615, 1971.
38. Parshad R, Gantt R, Sanford KK and Jones GM: Chromosomal 
radiosensitivity of human tumor cells during the G2 cell cycle 
period. Cancer Res 44: 5577-5582, 1984.
39. Paoletti A, Giocanti N, Favaudon V and Bornens M: Pulse 
treatment of interphasic HeLa cells with nanomolar doses of 
docetaxel affects centrosome organization and leads to cata-
strophic exit of mitosis. J Cell Sci 110: 2403-2415, 1997.
40. Morse DL, Gray H, Payne CM and Gillies RJ: Docetaxel induces 
cell death through mitotic catastrophe in human breast cancer 
cells. Mol Cancer Ther 4: 1495-1504, 2005.
41. Pradier O, Rave-Fränk M, Lehmann J, Lücke E, Boghun O, 
Hess CF and Schmidberger H: Effects of docetaxel in combina-
tion with radiation on human head and neck cancer cells (zMK-1) 
and cervical squamous cell carcinoma cells (CaSki). Int J Cancer 
91: 840-845, 2001.
42. Clarke SJ and Rivory LP: Clinical pharmacokinetics of docetaxel. 
Clin Pharmacokinet 36: 99-114, 1999.
43. Bruno R and Sanderink GJ: Pharmacokinetics and metabolism 
of Taxotere (docetaxel). Cancer Surv 17: 305-313, 1993.
44. Brunsvig PF, Andersen A, Aamdal S, Kristensen V and Olsen H: 
Pharmacokinetic analysis of two different docetaxel dose levels 
in patients with non-small cell lung cancer treated with docetaxel 
as monotherapy or with concurrent radiotherapy. BMC Cancer 7: 
197, 2007.
45. Milas L, Hunter NR, Mason KA, Kurdoglu B and Peters LJ: 
Enhancement of tumor radioresponse of a murine mammary 
carcinoma by paclitaxel. Cancer Res 54: 3506-3510, 1994.
46. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y and 
Peters LJ: Role of reoxygenation in induction of enhancement 
of tumor radioresponse by paclitaxel. Cancer Res 55: 3564-3568, 
1995.
47. McIlwrath AJ, Vasey PA, Ross GM and Brown R: Cell 
cycle arrests and radiosensitivity of human tumor cell lines: 
Dependence on wild-type p53 for radiosensitivity. Cancer Res 
54: 3718-3722, 1994.
